Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
暂无分享,去创建一个
Mitch Dowsett | Roger A'Hern | M. Dowsett | S. Ebbs | J. Salter | I. Smith | R. A’Hern | J. Dixon | Ian E Smith | G. Walsh | Stephen R Ebbs | J Michael Dixon | Anthony Skene | Janine Salter | Simone Detre | Margaret Hills | Geraldine Walsh | J. Dixon | M. Hills | A. Skene | S. Detre | I. Smith
[1] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[2] W. Holzgreve,et al. Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples , 2006, Breast Cancer Research.
[3] I. Ellis,et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[4] A. Ashworth,et al. Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.
[5] Atac Secretariat. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002 .
[6] M. Dowsett,et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[7] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[8] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[10] 青儀 健二郎,et al. What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .
[11] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[12] Mitch Dowsett,et al. Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Sotiriou,et al. Challenges in breast cancer clinical trial design in the postgenomic era , 2004, Current opinion in oncology.
[14] A. Howell,et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.
[15] M. Dowsett,et al. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] M. Dowsett,et al. Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer. , 1998, Journal of clinical pathology.
[17] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.